argenx announces results of Annual General Meeting of Shareholders
May 07 2024 - 5:30PM
May 7, 2024 – 5:30pm ET
Amsterdam, the Netherlands –
argenx SE (Euronext & Nasdaq: ARGX), a global immunology
company committed to improving the lives of people suffering from
severe autoimmune diseases, announced the results of its Annual
General Meeting of shareholders held today.
All items on the agenda received a majority of
votes in favor except for agenda item 5 (adoption of the
remuneration policy).
As part of the approved resolutions:
- The Company's annual report and
annual accounts for the financial year ending December 31, 2023
were approved;
- Dr. Brian L. Kotzin has been
appointed as non-executive director to the Board of Directors for a
term of four years. Dr. Kotzin brings broad medical and scientific
research and development experience to the Board, supporting the
Company’s innovation mission across therapeutic areas.
- Peter Verhaeghe and Dr. Pamela
Klein have been re-appointed as non-executive directors to the
Board of Directors for a term of 2 years;
- The Board of Directors was
authorized to issue shares and grant rights to subscribe for shares
in the share capital of the Company for up to 10% of the
outstanding share capital at the date of the meeting and for a
period of 18 months from the meeting and to limit or exclude
statutory pre-emptive rights;
- An amendment of the articles of
association of the Company was approved
- Deloitte Accountants B.V. has been
appointed as the Company's auditor for the 2024 financial year;
and
- Ernst & Young Accountants LLP
has been appointed as the Company's auditor for the 2025 financial
year.
The voting result and all documents relating to
the shareholders’ meeting will be available on the argenx website
at www.argenx.com/investors/shareholder-meetings.
About argenxargenx is a global
immunology company committed to improving the lives of people
suffering from severe autoimmune diseases. Partnering with leading
academic researchers through its Immunology Innovation Program
(IIP), argenx aims to translate immunology breakthroughs into a
world-class portfolio of novel antibody-based medicines. argenx
developed and is commercializing the first-and- only approved
neonatal Fc receptor (FcRn) blocker in the U.S., the EU and UK, and
Japan. The Company is evaluating efgartigimod in multiple serious
autoimmune diseases and advancing several earlier stage
experimental medicines within its therapeutic franchises. For more
information, visit https://www.argenx.com/ and follow us on
LinkedIn, Twitter, and Instagram.
For further information, please
contact:
Media:Ben
PetokBpetok@argenx.com
Investors:Alexandra Roy
(US)aroy@argenx.com
Lynn Elton (EU)lelton@argenx.com
Argen X (EU:ARGX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Argen X (EU:ARGX)
Historical Stock Chart
From Dec 2023 to Dec 2024
